CR Double-Crane(SH:600062)2023-03-27 16:00Financial Performance - The total revenue for 2022 was CNY 9,446,925,267.13, representing a 3.68% increase compared to 2021[19]. - The net profit attributable to shareholders for 2022 was CNY 1,163,649,615.44, which is a 24.36% increase from the previous year[19]. - The net profit after deducting non-recurring gains and losses was CNY 1,088,710,800.45, reflecting a 25.09% increase year-on-year[19]. - The basic earnings per share for 2022 was CNY 1.1235, up 25.26% from CNY 0.8969 in 2021[20]. - The weighted average return on equity increased to 11.71% in 2022, up by 1.93 percentage points from 2021[20]. - The total assets at the end of 2022 were CNY 14,482,536,656.83, a 5.90% increase compared to the end of 2021[19]. - The net cash flow from operating activities for 2022 was CNY 1,341,669,648.48, showing a slight increase of 0.06% from the previous year[19]. - The total net assets attributable to shareholders at the end of 2022 were CNY 10,022,611,149.67, a 1.18% increase from the end of 2021[19]. - The company achieved a total operating revenue of RMB 9,446,925,267.13, representing a year-on-year increase of 3.68%[34]. - The operating cost for the period was RMB 4,231,814,948.90, which increased by 5.01% compared to the previous year[34]. Dividend Distribution - The company plans to distribute a cash dividend of 2.89 CNY per 10 shares to all shareholders, resulting in an estimated total cash dividend of approximately 300.49 million CNY based on the current total share count[6]. - The total cash dividend for 2022, including the semi-annual dividend, is expected to be around 891.74 million CNY, representing a cash dividend payout ratio of approximately 76.63%[6]. - The total cash dividend for the year 2022 amounted to RMB 891,739,671.02, accounting for 76.63% of the net profit attributable to ordinary shareholders in the consolidated financial statements[129]. - The cash dividend per 10 shares for the year 2022 is proposed to be RMB 2.89 (including tax), with an estimated total cash dividend of RMB 300,492,807.79 based on the share count as of December 31, 2022[129]. Corporate Governance - The company has received a standard unqualified audit report from Ernst & Young Hua Ming[5]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company has not reported any non-operational fund occupation by controlling shareholders or related parties[8]. - There are no violations of decision-making procedures regarding external guarantees[8]. - The company has established a clear and independent business operation, with no overlap in major product structures with the controlling shareholder[94]. - The company has continuously improved its internal control and compliance management system, ensuring effective operation and risk assessment[94]. - The company has established an independent financial department with a standardized accounting system, ensuring no interference from the controlling shareholder[94]. - The company has held five shareholder meetings in 2022, addressing key issues such as amendments to the articles of association and the approval of the 2021 restricted stock incentive plan[96]. Research and Development - The company launched 17 generic drugs and 6 active pharmaceutical ingredients in 2022, enhancing its R&D pipeline and technical innovation capabilities[25]. - The company reported a total of CNY 74,938,814.99 in non-recurring gains for 2022, compared to CNY 65,350,822.26 in 2021[22]. - The company has established a technology innovation committee in 2022 to enhance its R&D capabilities and collaboration with academic institutions[64]. - The company is focusing on differentiated innovation in the innovative drug sector, supported by recent regulatory improvements aimed at accelerating drug approval processes[27]. - The company aims to enhance its innovation culture and attract high-level R&D talent to accelerate the development of innovative drugs[65]. Market Strategy - The company aims to become a world-class pharmaceutical enterprise driven by innovation, focusing on chronic disease management, specialty business, and infusion business during the "14th Five-Year Plan" period[28]. - The company is actively participating in the ongoing reforms in the pharmaceutical industry, ensuring compliance with new regulations and enhancing operational efficiency[27]. - The company is committed to providing economical, safe, and effective medications to patients, responding to the increasing clinical demand driven by an aging population and rising life expectancy[27]. - The company is exploring digital economy developments in the healthcare sector, particularly in chronic disease management, to reduce costs and enhance specialization[57]. Acquisitions and Investments - The company acquired a 50.11% stake in Shenzhou Biotechnology, enhancing its capabilities in the biopharmaceutical sector[25]. - The company increased its stake in Tiandong Pharmaceutical to 70% by purchasing 31.25% from China Resources Pharmaceutical for RMB 307,187,500[41]. - The company has engaged Ernst & Young Hua Ming as its auditor for the 2022 fiscal year, with an audit fee of 2.22 million yuan[166]. - The company has completed the industrial and commercial change registration for the acquisition of Tiandong Pharmaceutical[171]. Environmental Responsibility - The company has established an environmental protection mechanism and complies with relevant regulations without any need for rectification[139]. - The company has reported no instances of exceeding emission standards for major pollutants during the reporting period[141]. - The company has implemented carbon reduction measures, including the use of photovoltaic power generation and energy-saving equipment, resulting in zero reduction in carbon dioxide equivalent emissions for the reporting period[151]. - The company has initiated a new round of environmental protection and carbon reduction projects, demonstrating a commitment to sustainable development and low-carbon transformation[153]. Employee and Executive Management - The total pre-tax compensation for executives in the reporting period amounted to 1,688.90 million yuan[99]. - The company has a total of 5,764 production staff, 2,919 sales staff, and 2,043 technical staff among its employees[121]. - The company has established a market-oriented compensation system that links employee performance to company performance[122]. - The company has implemented a performance-oriented evaluation and incentive mechanism for senior management, linking their compensation to the completion of annual operational goals[134]. Risks and Challenges - The company faces market competition risks in chronic disease medication and basic infusion fields, with plans to enhance product portfolio and expand into oncology and orthopedics to improve competitive advantage[91]. - There is a risk of product price declines due to normalized centralized procurement, which may affect the company's profitability; the company plans to adjust product structure and enhance quality through innovation[91]. - Rising production factor costs, including raw materials and labor, pose a risk; the company aims to implement lean production and improve efficiency to mitigate these costs[91]. - New drug development is a complex and costly process with inherent risks; the company is focusing on project management and enhancing R&D efficiency as part of its "14th Five-Year Plan" strategy[91].